Abstract: A fully-automatic aluminum thermal-spraying corrosion prevention production line based on robots and visual recognition is provided. The production line comprises an automatic feeding system comprising feeding carrying and conveying mechanisms; a laser derusting system comprising a derusting robot, a laser cleaning nozzle and derusting conveying mechanisms; an aluminum thermal-spraying system comprising an aluminum spraying robot and an aluminum thermal-spraying gun; an automatic rolling system comprising a rolling pedestal, a first rolling wheel, a second rolling wheel and a rolling drive mechanism; a laser cutting system; and a discharging and stacking system.

Abstract: A digital and informationized fully-automatic aluminum thermal-spraying production line includes: an automatic feeding system including first transfer mechanisms and first carrying conveying mechanisms; a laser cleaning system including a laser cleaning tank, laser cleaning nozzles and cleaning conveying mechanisms; a first transfer system including second carrying conveying mechanisms and second transfer mechanisms; an aluminum thermal-spraying system including traveling mechanisms, turning mechanisms and an aluminum spraying mechanism, the traveling mechanisms being configured to convey workpieces on the second carrying conveying mechanisms onto the turning mechanisms one-by-one, the turning mechanisms being configured to turn the workpieces by a preset angle, and the aluminum spraying mechanism being configured to perform aluminum arc-spraying on the workpieces.

Abstract: The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R.

Abstract: A dosimetry assessment method for an organ at risk (OAR) in an esophageal radiotherapy plan includes: acquiring volumetric-modulated arc therapy (VMAT) plan data of a patient with esophageal cancer, and obtaining a distance-target histogram (DTH); subjecting a geometric feature vector of the DTH to dimension reduction to obtain a dimension-reduced geometric feature vector; establishing a deep belief network (DBN) model, and completing training the DBN model; non-linearly fitting a correlation between a dose feature vector and the dimension-reduced geometric feature vector to obtain a dose feature vector with a dimension being identical to a dimension of the dimension-reduced geometric feature vector; and reconstructing the dose feature vector through a decoding layer of an autoencoder structure to obtain a dose feature vector with a dimension being identical to a dimension of the geometric feature vector before the dimension reduction, and finally obtaining a dose-volume histogram (DVH) for predicting the OAR

Abstract: A compound represented by formula (I) and a pharmaceutical composition thereof. The compound represented by formula (I) may be used as an adenosine receptor inhibitor, especially as an A2A and/or A2B inhibitor, for example, the compound may be used to prevent or treat diseases related to A2A and/or A2B activity or expression.

Abstract: The present application provides a pipeline adapter including a first connection block, a second connection block, a fastener and a seal ring. The first connection block is provided with a first channel and a first annular positioning groove disposed around the first channel. The second connection block is provided with a second channel communicating with the first channel and a second annular positioning platform fitting inside the first annular positioning groove. The second annular positioning platform is disposed around the second channel. The fastener connects the first connection block to the second connection block. The seal ring fits between the first annular positioning groove and the second annular positioning platform. The pipeline adapter is convenient to use, has a favorable sealing effect, and facilitates pipeline connection of a refrigeration system.

Abstract: A compound represented by formula (I) and a pharmaceutical composition thereof. The compound represented by formula (I) can be used as an adenosine receptor inhibitor, in particular, A2A and/or A2B inhibitors, for example, can be used for preventing or treating diseases related to A2A and/or A2B activity or expression level.

Abstract: A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.

Abstract: The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts, hydrates, and solvates thereof. It also provides pharmaceutical compositions, preparation and utilities thereof in treating diseases and disorders including cancers.

Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.

Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.

Abstract: A heterocyclic compound is described, which is an inhibitor of FGFR (fibroblast growth factor receptor). Specifically, it is a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates. The definition of each group in the formula (I) is as described in the specification. The compound of the present invention has FGFR inhibitory activity and can be used for preventing or treating a disease associated with FGFR activity or expression.

Abstract: The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R.

Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.

Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosterics, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.

Abstract: A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.

Abstract: The present application provides a pipeline adapter including a first connection block, a second connection block, a fastener and a seal ring. The first connection block is provided with a first channel and a first annular positioning groove disposed around the first channel. The second connection block is provided with a second channel communicating with the first channel and a second annular positioning platform fitting inside the first annular positioning groove. The second annular positioning platform is disposed around the second channel. The fastener connects the first connection block to the second connection block. The seal ring fits between the first annular positioning groove and the second annular positioning platform. The pipeline adapter is convenient to use, has a favorable sealing effect, and facilitates pipeline connection of a refrigeration system.

Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.

Abstract: Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosterics, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.